Page last updated: 2024-09-05

orantinib and Cancer of Pancreas

orantinib has been researched along with Cancer of Pancreas in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abbruzzese, JL; Davis, DW; Demetri, GD; Herbst, RS; Heymach, JV; McConkey, DJ; Rashid, A; Raut, CP; Shen, Y; Stadler, WM; Takamori, R; Wen, S; Xiong, HQ	1
Cherrington, JM; Griffin, RJ; Park, H; Song, CW; Wild, R; Williams, BW	1

Other Studies

2 other study(ies) available for orantinib and Cancer of Pancreas

Article	Year
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2005
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer research, 2002, Mar-15, Volume: 62, Issue:6 Topics: Animals; Cell Division; Chemotherapy, Adjuvant; Female; Fibrosarcoma; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Nude; Oxindoles; Pancreatic Neoplasms; Propionates; Pyrroles; Radiation-Sensitizing Agents; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2002

Article

Year

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1

Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2

2005

Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.

Cancer research, 2002, Mar-15, Volume: 62, Issue:6

Topics: Animals; Cell Division; Chemotherapy, Adjuvant; Female; Fibrosarcoma; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Nude; Oxindoles; Pancreatic Neoplasms; Propionates; Pyrroles; Radiation-Sensitizing Agents; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor

2002